Article

Accommodating IOL ad campaign for seniors launched by Bausch & Lomb

Bausch & Lomb launched a new advertising campaign geared toward baby boomers and seniors about its FDA-approved accommodating IOL (Crystalens).

Aliso Viejo, CA-Bausch & Lomb launched a new advertising campaign geared toward baby boomers and seniors about its FDA-approved accommodating IOL (Crystalens).

The lens is the only FDA-approved accommodating IOL in the United States and, according to the company, aims to eliminate a patient’s cataract and provide a patient with a full range of vision.

“This direct-to-consumer advertising campaign is showing great results in helping the +50 consumer understand that they can do something about their cataracts and their glasses with one surgery,” said Amy Jacobs, director of global marketing, Bausch & Lomb. “The advertising encourages patients to talk to their ophthalmologist about whether they are candidates for Crystalens or to visit the Crystalens web site (www.crystalens.com) to learn more about this exciting vision-correction alternative.”

Advertising research conducted by Bausch & Lomb found that “only a small fraction of people realize that not all IOLs are the same.” It also indicated that “a number of patients are willing to pay a little extra money in order to get better vision.”

The advertising campaign, which has resumed in Dallas, Raleigh-Durham, North Carolina, and St. Louis, generated a 10-fold increase in traffic to the Web site. Local television, radio, and newspapers will target consumers who are aged 50 years or more in key Florida markets including Fort Meyers/Naples, Jacksonville, Miami/Fort Lauderale, Tallahasse, Tampa/St. Peterburg, and West Palm Beach.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.